Maraviroc
- Generic Name
- Maraviroc
- Brand Names
- Celsentri, Selzentry
- Drug Type
- Small Molecule
- Chemical Formula
- C29H41F2N5O
- CAS Number
- 376348-65-1
- Unique Ingredient Identifier
- MD6P741W8A
- Background
Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.
- Indication
Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.
- Associated Conditions
- CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
MARCH Vascular Endothelium Substudy
- Conditions
- Cardiovascular Disease
- Interventions
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 34
- Registration Number
- NCT01585753
- Locations
- 🇦🇷
Fundacion IDEAA, Buenos Aires, Argentina
🇦🇷Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
🇩🇪Johann Wolfgang Goethe-University Hospital, Medical HIVCENTER, Frankfurt, Frankfurt am Main, Germany
Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)
- Conditions
- HIV Infection
- Interventions
- Drug: Tenofovir, emtricitabine, lopinavir/r
- First Posted Date
- 2012-02-15
- Last Posted Date
- 2015-04-01
- Lead Sponsor
- Hospital Clinic of Barcelona
- Target Recruit Count
- 240
- Registration Number
- NCT01533272
- Locations
- 🇪🇸
Hospital Clinic de Barcelona, Barcelona, Spain
Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women
- Conditions
- HIV Infection
- Interventions
- Other: Emtricitabine placeboOther: Tenofovir disoproxil fumarate placeboOther: Maraviroc placebo
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 594
- Registration Number
- NCT01505114
- Locations
- 🇺🇸
Weill Cornell Chelsea CRS, New York, New York, United States
🇺🇸New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States
🇺🇸UCLA CARE Center CRS, Los Angeles, California, United States
A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)
- Conditions
- Human Immunodeficiency Virus (HIV)HIV Associated Neurocognitive Disorders (HAND)
- Interventions
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Bruce Brew
- Target Recruit Count
- 19
- Registration Number
- NCT01449006
- Locations
- 🇦🇺
St. Vincent's Hospital, Sydney, New South Wales, Australia
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
Safety Study of Maraviroc's Effect on Human Osteoclasts
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- National Center for Global Health and Medicine, Japan
- Target Recruit Count
- 16
- Registration Number
- NCT01428986
- Locations
- 🇯🇵
National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 262
- Registration Number
- NCT01400412
- Locations
- 🇺🇸
University of Colorado Hospital CRS (6101), Aurora, Colorado, United States
🇺🇸Univ. of South Florida (USF) College of Medicine ATN CRS (33001), Tampa, Florida, United States
🇺🇸Washington U CRS (2101), Saint Louis, Missouri, United States
Maraviroc Abacavir STudy - Effect on Endothelial Recovery
- First Posted Date
- 2011-07-07
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- S.F.L. van Lelyveld
- Target Recruit Count
- 24
- Registration Number
- NCT01389063
- Locations
- 🇳🇱
University Medical Center Utrecht, Utrecht, Netherlands
Maraviroc Switch Collaborative Study
- First Posted Date
- 2011-06-29
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 399
- Registration Number
- NCT01384682
- Locations
- 🇦🇷
Fundacion IDEAA, Buenos Aires, Argentina
🇦🇷Hospital Privado- Centro Medico Cordoba, Cordoba, Argentina
🇦🇺Holdsworth House Medical Practice, Sydney, New South Wales, Australia
Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring
- Conditions
- HIV Infections
- Interventions
- Drug: Dapivirine-Maraviroc Vaginal RingOther: Placebo Vaginal Ring
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2015-09-10
- Lead Sponsor
- International Partnership for Microbicides, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT01363037
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸The Fenway Institute/Fenway Community Health, Boston, Massachusetts, United States
🇺🇸Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients
- First Posted Date
- 2011-05-05
- Last Posted Date
- 2016-07-12
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 407
- Registration Number
- NCT01348308
- Locations
- 🇫🇷
Hôpital Henri Mondor, Creteil, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.